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The conditions under which tumor necrosis factor- § (TNF) induces apoptosis in primary
microvascular endothelial cells (MVEC) were investigated. In the absence of sensitizing
agents, TNF induced apoptosis after 3 days of incubation in confluent MVEC. In contrast,
upon addition of the transcriptional inhibitor actinomycin D (Act. D), confluence was no long-
er required and apoptosis occurred already after 16 h. To assess the role of either TNF
receptor (TNFR) type in apoptosis, MVEC isolated from mice genetically deficient in TNFR1
(Tnfr1° mice) or TNFR2 (Tnfr2° mice) were incubated with TNF in the presence or absence of
Act. D. Under sensitized conditions, Tnfr2° MVEC were lysed like controls, whereas Tnfr1°
MVEC were completely resistant, indicating an exclusive role for TNFR1. In contrast, in the
absence of Act. D, confluent monolayers of wild-type cells were lysed by TNF, but both
Tnfr1° and Tnfr2° MVEC were resistant to TNF-mediated toxicity, indicating a requirement
for both TNFR types. Overexpression of the anti-apoptotic protein bcl-xL in MVEC led to a
protection against the direct, but not the sensitized cytotoxicity of TNF. In conclusion, in
pathophysiologically relevant conditions, both TNFR appear to be required for TNF-induced
apoptosis in MVEC.





Abbreviations: MVEC: Microvascular endothelial cells
LVEC: Large vessel endothelial cells Act. D: Actinomycin
D CHX: Cycloheximide ECGS: Endothelial cell growth
supplement m: Mouse h: Human wt: Wild-type
1 Introduction
The capacity of TNF to induce hemorrhagic necrosis of
certain tumors in vivo [1] has been shown to be partly
mediated by endothelial injury of the tumor microvascu-
lature [2, 3]. Thus, microvascular endothelial cells
(MVEC) are important target cells for the tumor necrotic
activity of TNF. Moreover, MVEC are critical in the devel-
opment of tissue lesions associated with an overproduc-
tion of TNF, as can be found in septic shock (lung MVEC)
[4] or cerebral malaria (brain MVEC) [5]. In vivo observa-
tions have revealed that MVEC are more sensitive to TNF
than large vessel endothelial cells (LVEC) following sys-
temic infusion [6]. On the other hand, in vitro, lung MVEC
have been reported to be resistant towards the direct
lytic activity of TNF [7], in contrast to LVEC, which vari-
ous groups found to undergo apoptosis in response to
TNF [7–10].
To investigate whether TNF can lyse MVEC under spe-
cific conditions, we isolated brain MVEC and tested
them for their sensitivity to TNF, using confluent versus
sub-confluent conditions. Moreover, we wished to
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Figure 1. Conditions under which TNF induces toxicity in
MVEC. (A) Cytotoxic activity of mTNF on CBA/J brain MVEC
under confluent (5 × 104 cells/well) vs. sub-confluent
(3 × 104 cells/well) conditions after 72 h of incubation. (B)
Cytolytic activity of mTNF on CBA/J brain MVEC in the pres-
ence or absence of 1 ? g/ml Act. D and/or 3 ? g/ml CHX after
24 h of incubation. Cells were pretreated for 15 min with
Act. D and for 4 h with CHX before the addition of mTNF. All
experiments represent the means of triplicates of three
experiments ± SD.
Figure 2. mTNF (10 ng/ml) induces apoptosis in brain
MVEC. The number of apoptotic cells was assessed by acri-
dine orange staining after 48 h of incubation with 10 ng/ml
mTNF or after 16 h of incubation with 10 ng/ml mTNF and
1 ? g/ml Act. D. The data represent the means of quadrupli-
cates ± SD.
assess the role of both TNFR in TNF-induced cytotoxic-
ity. Since MVEC express both the 55-kDa (TNFR1) and
the 75-kDa (TNFR2) TNFR, we assessed the importance
of each of these receptors by using MVEC isolated from
TNFR gene-deficient mice [11, 12]. In this respect, it
should be noted that TNFR1 contains a death domain
[13, 14], whereas TNFR2 does not. However, the latter
TNFR was recently shown to be implicated in apoptosis
induction in activated T cells, and this occurred through
inhibition of the expression of the anti-apoptotic protein
bcl-xL [15].
2 Results
2.1 Either confluence or transcriptional inhibition
are required for cytolytic activity of TNF on
MVEC
Under sub-confluent conditions (3 × 104 cells/well at the
start of the assay), no lysis of CBA/J brain MVEC was
detectable after 24, 48, 72 or 96 h of incubation with
mouse (m)TNF (up to 1000 IU/ml), as measured by ethi-
dium homodimer incorporation (data for 72 h incubation
are shown in Fig. 1A). In contrast, under initial confluent
conditions (5 × 104 cells/well), these cells were lysed
after 72 h of incubation with mTNF in a dose-dependent
manner (Fig. 1A). In the presence of the transcriptional
inhibitor actinomycin D (Act. D) (1 ? g/ml) however, brain
MVEC became sensitive to TNF-induced cytolysis, even
under sub-confluent conditions, whereas Act. D alone
had no effect (Fig. 1B). This cytolysis was already detect-
able after 24 h of incubation (Fig. 1B). When the protein
synthesis inhibitor cycloheximide (CHX; 3 ? g/ml) was
added 4 h prior to TNF and Act. D, i.e. under conditions
that are optimal for protein synthesis inhibition [16], the
level of TNF and Act. D-induced MVEC cytolysis was
reduced to that observed with CHX alone, i.e. ˚ 15 %
(Fig. 1B). All these results were confirmed using murine
CBA/J lung MVEC and bovine adrenocortical MVEC
(data not shown).
2.2 TNF kills MVEC by means of apoptosis
Apoptosis was assessed by means of fluorescence
microscopy by counting cells stained with acridine
orange which displayed the typical characteristics of
apoptosis, such as chromatin condensation (seen as
intensified fluorescence), contraction of the cytoplasm
and the formation of projections or blebs. Apoptosis was
induced in confluent brain MVEC treated for 48 h with
10 ng/ml mTNF. Under these conditions, 37 ± 5 % of the
TNF-treated cells were apoptotic, compared to 5 ± 2 %
in the control group (Fig. 2). In the presence of Act. D,
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Figure 3. Comparison of cytotoxic activity of hTNF vs.
mTNF in CBA/J brain MVEC in the presence (A) or absence
(B) of Act. D. All values represent the means of quadrupli-
cates of two experiments ± SD.
apoptosis could be detected from 6 h on (20 ± 3 % in the
TNF-treated group vs. 4 ± 1 % in the Act. D controls),
and after 16 h, 84 ± 6 % of cells were affected in the
mTNF-treated group vs. 8 ± 3 % in the control group
(Fig. 2).
2.3 Comparison of cytotoxicity of human versus
mTNF in mouse brain MVEC
As shown in Fig. 3A, human (h)TNF, which does not inter-
act with mouse TNFR2 [17], had a 10-fold reduced
capacity in the presence of Act. D to induce apoptosis in
CBA/J brain MVEC, which express both TNFR (data not
shown). In sharp contrast, in the absence of Act. D,
hTNF had a more than 100-fold reduced capacity, as
compared to mTNF, to induce cell killing (Fig. 3B). These
results thus suggested that TNFR2 is required for TNF-
induced cytotoxicity in the absence, but not in the pres-
ence of Act. D. To further substantiate this hypothesis,
we studied TNF-induced cytotoxicity in MVEC isolated
from Tnfr1° and Tnfr2° mice.
2.4 TNFR expression in brain MVEC isolated
from wt, Tnfr1° and Tnfr2° mice
Brain MVEC isolated from B6 × 129 wild-type (wt) mice
expressed both types of TNFR, as assessed by a cell-
based immunofluorescence assay. Cells isolated from
Tnfr1° mice and Tnfr2° mice expressed the remaining
receptor type at a level comparable to wt MVEC (Fig. 4).
The difference in sensitivity to TNF between confluent
and sub-confluent cells was not attributable to a different
level of expression of either TNFR: we did not detect any
increased level of either receptor under confluent vs.
sub-confluent conditions (data not shown).
2.5 Role of TNFR in sensitized versus direct TNF
cytotoxicity
When treated with both mTNF and Act. D in a 24-h
assay, brain MVEC from Tnfr1° mice were completely
resistant to cytolysis, whereas cells isolated from Tnfr2°
mice behaved in a manner comparable to that of cells
isolated from control mice (Fig. 5A), which is consistent
with results presented in Fig. 3A. Act. D alone had no
toxic effect on the MVEC from either wt, Tnfr1° or Tnfr2°
mice. In contrast to the experiments performed in the
presence of Act. D, brain MVEC from both Tnfr1° and
Tnfr2° mice, incubated with mTNF for 72 h, were pro-
tected against cytolysis, whereas wt cells were lysed
(Fig. 5B). These results were confirmed using CBA/J lung
MVEC (data not shown).
2.6 Overexpression of bcl-xL protects against
direct, but not against sensitized TNF
cytotoxicity in MVEC
Recently, TNFR2 was shown to be implicated in apopto-
sis of activated T cells by means of inhibiting the expres-
sion of the anti-apoptotic protein bcl-xL [15]. Our previ-
ous results had indicated that TNFR2 is implicated in the
direct, but not in the sensitized cytotoxicity of TNF in
MVEC. Therefore, we wanted to investigate whether
overexpression of bcl-xL could protect against TNF
cytotoxicity implicating TNFR2. Transfected CBA brain
MVEC showed a marked increase in expression of bcl-
xL (Fig. 6B), as compared to non-transfected controls
(Fig. 6A). The transfected cells no longer required the
presence of endothelial cell growth supplement (ECGS)
to proliferate and still efficiently responded to TNF-
induced E-selectin expression (data not shown; Lucas et
al., manuscript in preparation). After 24 h of incubation in
the presence of Act. D, transfected MVEC, cultured
either with or without ECGS, were as sensitive to TNF
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Figure 4. Expression levels of TNFR1 and TNFR2 in MVEC
isolated from wt B6 × 129, Tnfr1° and Tnfr2° mice. The val-
ues represent the means of quadruplicates ± SD.
Figure 5. Comparison of sensitivity of brain MVEC isolated
from wt B6 × 129 mice vs. Tnfr1° and Tnfr2° mice towards:
(A) the combined lytic effect of mTNF and Act. D after 24 h
of incubation (3 × 104 cells/well), and (B) the direct lytic
effect of mTNF after 72 h of incubation (5 × 104 cells/well).
All values represent the means of quadruplicates of three
experiments ± SD.
Figure 6. Expression levels of bcl-xL in (A) wt brain CBA/J
MVEC and (B) pSFFV bcl-xL-transfected CBA/J brain
MVEC.
cytotoxicity as the non-transfected cells (Fig. 7A). In
sharp contrast, after 72 h of incubation, confluent mono-
layers of bcl-xL-transfected MVEC were resistant to
direct TNF cytotoxicity, whereas the control cells or the
cells microinjected with the control vector were effi-
ciently lysed (Fig. 7B).
3 Discussion
In vivo, both TNFR appear to be involved in the systemic
toxicity of TNF. Both Tnfr1° [11, 18, 19] and Tnfr2° mice
[12] were shown to be resistant to lethal doses of mTNF,
with resistance being more marked in the former [18].
Apart from being directly cytotoxic, TNF can indirectly
cause tissue damage, e.g. by means of inducing adhe-
sion molecules, such as ICAM-1, that increases the inter-
action between the endothelium and leukocytes [20, 21]
or platelets [22]. Moreover, the decreased activation of
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Figure 7. Comparison of sensitivity to (A) Act. D-sensitized
and (B) direct mTNF cytotoxicity between wt, control vector-
microinjected and bcl-xL-overexpressing CBA/J brain
MVEC. All values represent the means of triplicates of three
experiments ± SD.
the integrin § v g 3, an adhesion molecule which plays a
key role in tumor angiogenesis, by the combined treat-
ment of human endothelial cells with TNF and IFN- + , was
recently proposed to be one of the mechanisms impli-
cated in the anti-vascular activity of these cytokines [23].
Here, we have addressed the direct in vitro toxicity of
TNF on primary endothelial cells, which represent one of
the major target cells relevant for TNF pathology in vivo.
Most published studies have made use of LVEC that are
both morphologically and functionally different from
MVEC [24–26]. In this report, we have shown that mouse
MVEC, which are more affected than LVEC during TNF
infusion in vivo [6], can also be killed by mTNF in vitro,
provided they are at confluence; following a 72-h incuba-
tion with mTNF under these conditions, the cells
undergo apoptosis. However, under sub-confluent con-
ditions, MVEC are not lysed directly by TNF. The latter
result is in accordance with earlier findings of experi-
ments performed with bovine lung MVEC [7]. The reason
for this confluence-dependent sensitivity of MVEC
towards TNF remains unclear. We could not find signifi-
cant changes in TNFR expression between confluent
and sub-confluent cultures (data not shown), as was
reported for epithelial and myeloid cells [27]. Neither
could we find a role for membrane-bound TNF, which
should only be active during cell-cell contact and was
shown to be induced by exogenously added TNF in
HeLa cells [28]. In this respect, we could not inhibit cyto-
toxicity induced by hTNF in murine MVEC with neutraliz-
ing antibodies towards membrane-bound mTNF (kind
gift from M. Grell and K. Pfizenmaier, University of Stut-
tgart; data not shown), arguing against a role for endoge-
nously produced membrane-bound mTNF in cytotoxicity
in these cells.
Since the pretreatment of various cell types with Act. D
can either induce or increase sensitivity to TNF, results
obtained in the presence of transcriptional inhibitors do
not necessarily reflect the in vivo effect of TNF on these
cells. We found that in the presence of Act. D, TNFR1
was necessary and sufficient to mediate TNF-induced
apoptosis in MVEC. This result is in agreement with the
reported resistance of hepatocytes isolated from Tnfr1°
mice against cytotoxicity induced by the combination of
TNF and Act. D [16]. However, in contrast to confluent
MVEC, TNF had no direct cytotoxic effect on hepato-
cytes. Moreover, the combined effect of TNF and Act. D
disappeared after several in vitro passages of hepato-
cytes [16]. These results differ from our observations
with MVEC, which are directly killed by TNF at conflu-
ence and the sensitivity of which to TNF and Act. D does
not decrease upon serial passaging (tested for up to four
passages). The observation that MVEC isolated from
Tnfr2° mice are still efficiently lysed by a combined TNF
and Act. D treatment also indicates that TNFR1, still
expressed in these cells, is biologically active. The same
holds true for TNFR2 in Tnfr1° MVEC, which still medi-
ates up-regulation of ICAM-1 induced by membrane-
bound TNF [29].
In contrast to the results obtained under conditions of
transcriptional inhibition, both TNFR1 and TNFR2 are
required for direct TNF-induced MVEC apoptosis after
72 h. This result is in agreement with a previous report
that showed that both TNFR types are necessary to
induce DNA fragmentation in U-937 cells and cytotoxic-
ity in PC 60 cells [30, 31]. Thus, depending on the pres-
ence or absence of transcriptional inhibitors, different
pathways could be implicated in the TNF-induced killing
of MVEC. Likewise, others have provided evidence that
direct TNF-mediated cytotoxicity is genetically, pharma-
cologically, and temporally distinct from the cytotoxicity
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mediated by TNF during protein synthesis inhibition [32].
Recently, TNF was shown to trigger apoptosis in CHX-
treated human endothelial cells by means of an
IL-1-converting enzyme (ICE)-like protease-dependent
pathway, since this activity could be blocked by trans-
fected CrmA protein or Z-VAD.fmk peptide, but not by
transfected anti-apoptotic proteins such as bcl-2, bcl-xL
or A1 [33]. In contrast, the co-treatment of these cells
with TNF and C6-ceramide resulted in apoptosis inhibit-
able by transfected anti-apoptotic proteins but not by
ICE-like protease inhibitors [33]. Since most studies
assessing the cytotoxicity of TNF in endothelial cells
have been performed in the presence of transcriptional
or translational inhibitors, results from these experiments
should be interpreted with caution, since a role for
TNFR2 in cytotoxicity of endothelial cells would not be
detected under these conditions.
Since TNFR2, in contrast to TNFR1, does not have a
death domain [13, 14], its implication in apoptosis is
rather surprising. However, a recent report showed that
TNFR2 activation in activated T cells leads to a dimin-
ished expression of the anti-apoptotic protein bcl-xL in
these cells [15]. Bcl-xL was recently shown to inhibit the
association of the mammalian homologue of CED-4
(Apaf-1) and caspase 9, thus preventing the Apaf-1-
mediated maturation of caspase-9 [34]. Our experiments
with bcl-xL-overexpressing brain MVEC have indicated
that these cells are still sensitive to TNF-mediated effects
which are exclusively mediated by TNFR1, such as E-
selectin induction (completely absent in MVEC from
Tnfr1° mice) and Act. D combined cytotoxicity. The latter
result is in contrast to recent findings that MVEC overex-
pressing the anti-apoptotic protein A1, of the bcl-2 pro-
tein family, are resistant to the combined mTNF and
Act. D cytotoxicity [35]. Interestingly, bcl-xL-
overexpressing MVEC were resistant to effects involving
TNFR2, such as direct TNF cytotoxicity. Therefore, these
results suggest the existence of a cross-talk between
TNFR2 and bcl-xL in the absence of transcriptional inhi-
bition: one factor, upon activation (TNFR2) or overex-
pression (bcl-xL), inhibits the effect of the other. Thus,
the interaction between TNFR2 and bcl-xL might be one
of the mechanisms by which this TNFR type is impli-
cated in TNF cytotoxicity in MVEC. Although the basal
expression levels of anti-apoptotic proteins such as bcl-
2 and bcl-xL are consistently low or undetectable in
endothelial cells, these levels can be significantly
increased during viral infection of these cells. Indeed, the
expression of bcl-2 has recently been shown to be acti-
vated in endothelial cells chronically expressing the
human T cell lymphotropic virus type I, and this might be
pathophysiologically relevant [36]. Alternatively, TNFR2
was proposed to increase the TNFR1-mediated apopto-
sis of HeLa cells by up-regulating cytosolic phospholi-
pase A2 levels [37]. Moreover, a recent study has shown
that the absence of a TNFR2-associated protein TRAF2
can decrease the sensitivity of HeLa cells for TNF-
induced killing by a factor of 1000. Since the TNFR2-
associated signal transducer TRAF2 is a component of
the TNFR1 signaling complex [38], these results indicate
cross-talk between both TNFR for TNF-mediated cyto-
toxicity in these cells [28]. Since TNFR2, but not TNFR1
expression, is increased in lung MVEC in patients with
acute respiratory distress syndrome [39], in hepatocytes
from patients with chronic hepatitis B [40] and in brain
MVEC from mice with cerebral malaria [20, 29], this indi-
cates that this TNFR type, in addition to TNFR1, might
also play an important role in TNF-mediated pathology.
In conclusion, our results show that proliferating MVEC
are not killed by TNF alone, unless they are treated with
transcriptional inhibitors. This combined TNF and Act. D
toxicity is mediated by TNFR1. In contrast, in confluent
monolayers of MVEC, TNF directly induces apoptosis,
which is inhibited by either TNFR1 or TNFR2 deficiency.
These results suggest that in physiologically relevant
conditions, both TNFR are important for the direct cyto-
toxic effect of TNF on MVEC.
4 Materials and methods
4.1 Mice and cells
Male wt B6 × 129, as well as Tnfr1° [11] and Tnfr2° mice [12]
of an age of 8–10 weeks were provided by F. Hoffmann-La
Roche (Basel, Switzerland). Male CBA/J mice of the same
age were purchased from Iffa Credo, Les Oncins, France.
Mouse brain MVEC were isolated as described [41], using
magnetic beads (Dynabeads M-450, Dynal, Oslo, Norway),
covalently bound to a purified rat-anti-mouse platelet-
endothelial cell adhesion molecule (PECAM-1) mAb (kind
gift from Dr. B. Imhof, Geneva). The cells were characterized
for the presence of tight junctions, von Willebrand Factor
expression, acetylated low density lipoprotein uptake and
TNF-induced E-selectin expression (the latter being nega-
tive in cells lacking TNFR1). The cells were plated onto T25
flasks pre-coated with 2 % gelatin (Sigma, Buchs, Switzer-
land) and cultured at 37 °C in a 5 % CO2 atmosphere. MVEC
were passaged up to four times.
4.2 Buffers and reagents
MVEC were resuspended in DMEM containing 2 mM L-
glutamine, 100 U/ml penicillin, 10 ? g/ml streptomycin, 20 %
FCS, 40 U/ml heparin and 100 ? g/ml ECGS (Sigma).
Recombinant mTNF and hTNF (Innogenetics, Ghent, Bel-
gium) had a specific activity of 2 × 108 and 2 × 107 IU/mg,
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respectively. Act. D, CHX and acridine orange were obtained
from Sigma, Buchs, Switzerland.
4.3 TNF cytotoxicity assay
An ethidium homodimer-1 incorporation assay was used to
screen for lysis of endothelial cells. Ethidium homodimer-1
(Molecular Probes, Leiden, The Netherlands) is a high-
affinity red fluorescent DNA dye that is only internalized
through altered cell membranes. This assay has recently
been shown to be more sensitive than the MTT incorpora-
tion assay when screening for TNF cytotoxicity [42] and has
previously been used to screen for TNF-induced killing of
MVEC [43]. Briefly, MVEC (3 × 105 cells/ml) kept in DMEM
without phenol red (phenol red is a quencher of the ethidium
homodimer signal) were incubated for 24 h in the presence
of various concentrations of mTNF or hTNF and 1 ? g/ml
Act. D. Alternatively, confluent monolayers of MVEC (5 × 105
cells/ml) were treated for 72 h with various concentrations of
mTNF or hTNF. Subsequently, the MVEC were treated for
30 min at 37 °C with 8 mM ethidium homodimer solution. As
controls, cells pretreated for 30 min at room temperature
with 33 % ethanol (positive control) as well as cells incu-
bated in medium (negative control) were included. The fluo-
rescence signal was then read using 530 nm as excitation
wavelength and 620 nm as emission wavelength in a
CytoFluor® II fluorescence Multi-Well Plate Reader (PerSept-
ive Biosystems, MA), after which the percentage of dying
cells was calculated, using the following formula: [(experi-
mental signal) − (medium signal)]/[(ethanol signal) − (medium
signal)] × 100 %.
4.4 Apoptosis detection
Quantification of apoptotic cells was accomplished by acri-
dine orange uptake as described [44, 45]. Cells were incu-
bated with 1 ? g/ml acridine orange for 5 min and fixed in
4 % paraformaldehyde. Cellular morphology was subse-
quently assessed by fluorescence microscopy [44, 45].
Apoptosis was identified by the findings of condensation of
chromatin and blebbing of the cytoplasm [45]. A total of five
random microscope fields, each containing about 100 cells,
were examined under each experimental condition. The total
number of cells with histomorphological evidence of apop-
tosis was counted in each field.
4.5 Microinjection of DNA into MVEC
Construction of plasmids to express a FLAG tag attached to
bcl-xL protein has been described [46]. MVEC were cultured
in gelatin-precoated 3.5-cm diameter dishes for 2 days.
Rectangles (10 by 3 mm) containing 150 to 200 mouse brain
MVEC were drawn on the bottom of each dish to allow local-
ization of injected cells. pSFFV-bcl-xL-plasmid or the empty
pSFFV-plasmid solution at 100 ng/ml were injected into
MVEC nuclei with a mechanical Leitz manipulator and an
INJECT + MATIC microinjector [46]. After 10 days in culture
in the presence of medium with ECGS and 100 ? g/ml ge-
neticin, the percentage of microinjected MVEC expressing
FLAG-bcl-xL was determined by immunohistochemistry,
using M2, an mAb specific for FLAG (International Biotech-
nologies), followed by FITC-conjugated rat-anti-mouse IgG.
Greater than 80 % of the MVEC microinjected were posi-
tively stained. Cells microinjected with the control vector
survived the antibiotic treatment, while control cells were all
killed after 10 days in the presence of 100 ? g/ml geneticin.
4.6 Cell-based ELISA
MVEC cells (3 × 105 cells/ml) were left to adhere for 12 h in
96-well plates (Falcon) in DMEM + 20 % FCS. The plate was
then washed once with HBSS, 20 mM Hepes ( j washing
buffer), after which the cells were fixed for 45 min at room
temperature with DMEM + 1 % paraformaldehyde. After one
washing step, the cells were incubated for 45 min at room
temperature in blocking solution (PBS + 5 % BSA + 0.02 %
NaN3).
Subsequently, the wells were aspirated and 30 ? l of either a
polyclonal rabbit-anti-mTNFR1 or a rabbit-anti-mTNFR2
[47] was added for 45 min at room temperature. To assess
non-specific binding, the reactivity of rabbit-anti-mTNFR1
with MVEC from Tnfr1° and of rabbit-anti-mTNFR2 with
MVEC from Tnfr2° was measured. After two washing steps,
50 ? l/well of a goat anti-rabbit-alkaline phosphatase com-
plex (Biogenex, 1 ? g/ml) was added for 75 min under
smooth agitation at room temperature. Finally, after two
washing steps with washing buffer and one washing step
with 2.5 M diethanolamine buffer, pH 9.5, 100 ? l/well of the
substrate solution, consisting of the substrate AttophosTM
(Europa Research Products, Ely, GB) (final concentration
1 mM) was diluted in 2.5 M diethanolamine buffer, pH 9.5, to
which levamisole (an inhibitor of endogenous alkaline phos-
phatase, final concentration 10 mM) was added. After 2 min
of incubation, the plate was read at 485 nm excitation wave-
length and 530 nm emission wavelength in a Cytofluor® II
fluorescence multi-well plate reader (PerSeptive Biosys-
tems).
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